Insulet (PODD) AI Stock Analysis

• Market Cap: $21.44B
• Dividend Yield: N/A
• Average Volume (3M): 908.38K
• Price to Earnings (P/E): 54.8
• Beta (1Y): 1.10
• Revenue Growth: 23.49%
• EPS Growth: 71.25%
• Country: US
• Employees: 3,900
• Sector: Healthcare
• Sector Strength: 58
• Industry: Medical - Devices
• EPS (TTM): 1.02
• Shares Outstanding: 70,374,920
• 10 Day Avg. Volume: 836,843
• 30 Day Avg. Volume: 908,385
• PEG Ratio: -60.42
• Price to Book (P/B): 42.87
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -533.25
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: 2.78
• Enterprise Value/Gross Profit: 13.63
• Enterprise Value/Ebitda: 12.48
• 1Y Price Target: $338.39
• Price Target Upside: 11.08% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 19

• Rating: 76 Outperform
• Price Target: $363.00 ▲(19.16%Upside)

Insulet Corporation demonstrates strong financial performance and growth potential, supported by robust revenue and margin improvements. While technical and valuation indicators suggest caution, strategic leadership changes and positive earnings guidance bolster confidence in future growth. The stock is well-positioned in its industry but requires careful monitoring of valuation metrics.

Positive Factors

Leadership

The addition of Ashley McEvoy to the management team should be viewed as a positive, contributing to the company's strength.

Product Differentiation

PODD is viewed as a top idea for robust growth driven by product differentiation and new indications.

Sales Performance

Insulet reported first-quarter results that handily exceeded expectations, with sales of $569 million, which beat estimates.

Negative Factors

Growth Challenges

While new indications and integrations are promising, they also present challenges in maintaining growth momentum.

Market Competition

PODD's premium trading price reflects its durable competitive edge, but this may also indicate intense market competition.

Market Expectations

Although Insulet's results exceeded expectations, the high growth rate sets a challenging benchmark for future performance.

Insulet Business Overview & Revenue Model

Company Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

How the Company Makes Money

Insulet makes money through the sale of its Omnipod Insulin Management System, which includes both the wearable pods and the associated Personal Diabetes Manager (PDM). The company generates revenue primarily from the sale of these consumable pods, which need to be replaced every few days, creating a recurring revenue model. Additionally, Insulet may earn revenue from partnerships and collaborations with healthcare providers, insurance companies, and other stakeholders in the diabetes management ecosystem. The company's earnings are also influenced by its ability to expand its customer base, market its products effectively, and innovate within the insulin delivery space.

Insulet Financial Statement Overview

Summary

Insulet's financial performance is strong, with notable revenue growth and robust gross profit margins. The balance sheet is solid with low financial leverage and high return on equity. Cash flow management is efficient, with positive free cash flow, though there is room for further optimization.

Income Statement

Insulet has demonstrated strong revenue growth, particularly noticeable in its TTM (Trailing-Twelve-Months) performance with a significant increase over previous years. The gross profit margin is robust at approximately 76.5%, indicating efficient production management. The net profit margin and EBIT margin have also improved, reflecting enhanced operational efficiency and profitability. However, compared to some industry peers, there is scope for further improvement in EBIT and EBITDA margins.

Balance Sheet

The balance sheet shows a solid equity position with a debt-to-equity ratio of approximately 0.06, indicating low financial leverage and risk. Insulet's return on equity (ROE) is impressive at approximately 30.22%, showcasing strong shareholder returns. The equity ratio is about 37.8%, affirming a stable financial structure, although there is room to enhance asset utilization.

Cash Flow

Insulet's cash flow management is commendable with positive free cash flow and a healthy operating cash flow to net income ratio. The free cash flow growth is stable, contributing to financial flexibility. However, there is potential to optimize capital expenditures further to enhance free cash flow generation.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.03B	2.07B	1.70B	1.31B	1.10B	904.40M
	Gross Profit
1.55B	1.45B	1.16B	805.60M	752.10M	582.30M
	EBIT
340.80M	308.90M	220.00M	-26.70M	66.70M	-600.00K
	EBITDA
428.10M	423.70M	323.60M	109.50M	139.60M	110.30M
	Net Income Common Stockholders
402.20M	418.30M	206.30M	4.60M	16.80M	6.80M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.28B	953.40M	704.20M	674.70M	791.60M	947.60M
	Total Assets
3.52B	3.09B	2.59B	2.25B	2.05B	1.87B
	Total Debt
83.10M	1.39B	1.42B	1.40B	1.25B	1.04B
	Net Debt
-1.20B	438.70M	711.60M	727.10M	457.20M	96.10M
	Total Liabilities
2.19B	1.88B	1.86B	1.77B	1.49B	1.27B
	Stockholders Equity
1.33B	1.21B	732.70M	476.40M	556.30M	603.60M
Cash Flow		Free Cash Flow
290.90M	305.40M	36.50M	-38.30M	-190.80M	-82.50M
	Operating Cash Flow
406.50M	430.30M	145.70M	119.00M	-68.10M	84.00M
	Investing Cash Flow
-137.90M	-146.20M	-119.40M	-191.10M	-82.70M	14.00M
	Financing Cash Flow
263.80M	-28.10M	-13.60M	-40.30M	40.70M	605.50M

Insulet Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 304.63
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PODD, the sentiment is Positive. The current price of 304.63 is below the 20-day moving average (MA) of 317.76, above the 50-day MA of 285.68, and above the 200-day MA of 262.81, indicating a neutral trend. The MACD of 3.70 indicates Positive momentum. The RSI at 49.22 is Neutral, neither overbought nor oversold. The STOCH value of 26.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PODD.

Insulet Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	81 Outperform	$32.15B	61.55	23.72%	―	9.11%	-17.87%
SNN	80 Outperform	$12.98B	31.14	7.82%	3.14%	4.58%	55.99%
STE	80 Outperform	$23.74B	38.03	9.46%	0.94%	0.32%	64.36%
PODD	76 Outperform	$21.44B	54.82	37.92%	―	23.49%	71.25%
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
PHG	50 Neutral	$21.92B	―	-7.10%	3.89%	-0.76%	-55.03%
TNDM	50 Neutral	$1.38B	―	-92.31%	―	27.65%	-28.22%

Insulet Corporate Events

Insulet Issues Redemption Notice for Convertible Notes

On June 6, 2025, Insulet Corporation amended its Credit Agreement to refinance $481.25 million in term loans, reducing the interest rate margin and maintaining similar terms to the previous loans. Additionally, Insulet issued a redemption notice on June 9, 2025, for its outstanding Convertible Senior Notes due 2026, with plans to redeem them by August 20, 2025, potentially impacting stock transactions as hedge positions are unwound.

The most recent analyst rating on (PODD) stock is a Buy with a $380.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.

Insulet Corporation Holds 2025 Annual Stockholders Meeting

Insulet Corporation held its 2025 Annual Meeting of Stockholders on May 22, 2025, where shareholders elected three Class III directors, approved executive compensation, and ratified the appointment of Grant Thornton LLP as the independent public accounting firm for the fiscal year ending December 31, 2025. Additionally, the Insulet Corporation 2025 Stock Option and Incentive Plan was approved, indicating continued shareholder support for the company’s strategic initiatives and governance practices.

The most recent analyst rating on (PODD) stock is a Hold with a $185.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.

Insulet Appoints Ashley McEvoy as New CEO

On April 28, 2025, Insulet Corporation announced the appointment of Ashley McEvoy as President and CEO, succeeding Jim Hollingshead. This leadership change is expected to further the company’s success, as McEvoy brings extensive experience in healthcare leadership and innovation. Under Hollingshead’s tenure, Insulet achieved market leadership in diabetes care with the launch of the Omnipod 5. The company also announced it expects to exceed its first-quarter revenue guidance and plans to raise its full-year 2025 guidance, indicating strong financial performance and growth potential. The planned Investor Day has been postponed due to the CEO transition.

Insulet Closes $450 Million Senior Notes Issuance

On March 20, 2025, Insulet Corporation closed its issuance and sale of $450 million in 6.50% Senior Notes due 2033, with net proceeds expected to be approximately $444 million. Additionally, Insulet entered into a Seventh Amendment to its Credit Agreement, extending the maturity of revolving credit commitments to March 20, 2030, and increasing the commitments to $500 million. The company also engaged in Note Repurchase Transactions, repurchasing $419 million of its Convertible Senior Notes due 2026, which will impact its outstanding debt and potentially influence stock market activities.

Insulet Announces Pricing of $450 Million Senior Notes

On March 18, 2025, Insulet Corporation announced the pricing of $450 million in senior unsecured notes due 2033, with an annual interest rate of 6.50%. The proceeds, estimated at $444.4 million, will be used to finance the redemption of existing convertible senior notes, cover offering-related expenses, and for general corporate purposes. The private placement is expected to close on March 20, 2025, and the notes are offered to qualified institutional buyers and non-U.S. persons under specific regulations.

Insulet Announces $450M Senior Notes Offering

On March 18, 2025, Insulet Corporation announced a proposed offering of $450 million in senior unsecured notes due 2033, intended to finance the redemption of its existing Convertible Senior Notes due 2026, cover related expenses, and for general corporate purposes. Additionally, Insulet plans to amend its Credit Agreement to extend the maturity of its revolving credit facility to 2030 and increase commitments by $200 million. These financial maneuvers aim to strengthen Insulet’s financial position, though they are subject to market conditions and may not proceed as planned.

Insulet CTO Mark Field Departs for New Opportunities

Mark Field, the Senior Vice President and Chief Technology Officer of Insulet Corporation, has left the company as of March 14, 2025, to pursue other opportunities. Amit Guliani, currently the Group Vice President of Software Engineering, will temporarily assume the role of acting Chief Technology Officer while the company searches for a permanent replacement. Insulet plans to enter into a Consulting Agreement with Mr. Field to ensure a smooth transition.